Structure via PubChem · Public domain (PubChem)
azilsartan
Sign in to saveAlso known as TAK 536, TAK-536, TAK536
Azilsartan, sold under the brand name Edarbi among others, is used for the treatment of hypertension. It is used as the prodrug azilsartan medoxomil, is an angiotensin II receptor antagonist, and was developed by Takeda.
Key facts
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- 60%
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 456077928
- Drug.image
- Azilsartan.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Edarbi, Azilva
- Drug.MedlinePlus
- a611028
- Drug.DailyMedID
- Azilsartan
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- C09
- Drug.ATC_suffix
- CA09
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.metabolism
- CYP2C9
via Wikipedia infobox
Chemical data
- Formula
- C25H20N4O5
- Molecular weight
- 456.4 g/mol
- IUPAC name
- 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
- SMILES
- CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O
- InChIKey
- KGSXMPPBFPAXLY-UHFFFAOYSA-N
- XLogP
- 4.4
- Polar surface area
- 115 Ų
- H-bond donors
- 2
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
~6 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Contraindications
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- References
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 456077928 | image = Azilsartan.svg | image_class = skin-invert-image | width = | alt = | caption = | USAN =
| pronounce = | tradename = Edarbi, Azilva | Drugs.com = | MedlinePlus = a611028 | DailyMedID = Azilsartan | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = C09 | ATC_suffix = CA09 | ATC_supplemental =
Excerpted from Wikipedia’s “azilsartan” article, available under the CC BY-SA 4.0 licence.